Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40,555 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.
Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, Skoulidis F, Byers LA, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Gibbons DL, Park K, Rinsurongkawong W, Lee JJ, Gandara D, Behl D, Shu CA, Riess JW, Baik C, Wakelee HA, Vaporciyan AA, Heymach JV, Zhang J, Le X. Wang K, et al. J Thorac Oncol. 2024 Mar;19(3):500-506. doi: 10.1016/j.jtho.2023.11.020. Epub 2023 Nov 25. J Thorac Oncol. 2024. PMID: 38012986 Free article.
Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified.
Sousa LG, Wang K, Torman D, Binks BJ, Rubin ML, Andersen CR, Lewis WE, Rivera MJ, Kaya D, El-Naggar AK, Hanna EY, Esmaeli B, Frank SJ, Bell D, Glisson BS, Rodon J, Meric-Bernstam F, Lee JJ, Ferrarotto R. Sousa LG, et al. Among authors: wang k. Cancer. 2022 Feb 1;128(3):509-518. doi: 10.1002/cncr.33968. Epub 2021 Oct 18. Cancer. 2022. PMID: 34661906 Free article.
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC.
Wang K, Du R, Roy-Chowdhuri S, Li ZT, Hong L, Vokes N, Elamin YY, Hume CB, Skoulidis F, Gay CM, Blumenschein G, Fossella FV, Tsao A, Zhang J, Karachaliou N, O'Brate A, Gann CN, Lewis J, Rinsurongkawong W, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Altan M, Le X. Wang K, et al. JTO Clin Res Rep. 2023 Jun 1;4(8):100533. doi: 10.1016/j.jtocrr.2023.100533. eCollection 2023 Aug. JTO Clin Res Rep. 2023. PMID: 37649681 Free PMC article.
Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy.
Qin K, Wang K, Li S, Hong L, Padmakumar P, Waree R, Hubert SM, Le X, Vokes N, Rai K, Vaporciyan A, Gibbons DL, Heymach JV, Lee JJ, Woodman SE, Chung C, Jaffray DA, Altan M, Lou Y, Zhang J. Qin K, et al. Among authors: wang k. Cancers (Basel). 2024 Feb 26;16(5):935. doi: 10.3390/cancers16050935. Cancers (Basel). 2024. PMID: 38473297 Free PMC article.
Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review.
Xia Y, Wang K, Zhao J, Arter Z, Zhang Y, Zhou J, Lu Y, Zeng L, Du R, Owens JA, Elamin YY, Gay CM, Skoulidis F, Tsao AS, Lu C, Cascone T, Gibbons DL, Zhang J, Chen O, Mok KKS, Nagasaka M, Li W, Heymach JV, Ignatius Ou SH, Li M, Le X. Xia Y, et al. Among authors: wang k. J Thorac Oncol. 2024 Nov 30:S1556-0864(24)02490-0. doi: 10.1016/j.jtho.2024.11.027. Online ahead of print. J Thorac Oncol. 2024. PMID: 39622411 Free article.
Development of a clinical prediction model for benign and malignant pulmonary nodules with a CTR ≥ 50% utilizing artificial intelligence-driven radiomics analysis.
Shi W, Hu Y, Chang G, Qian H, Yang Y, Song Y, Wei Z, Gao L, Yi H, Wu S, Wang K, Huo H, Wang S, Mao Y, Ai S, Zhao L, Li X, Zheng H. Shi W, et al. Among authors: wang k. BMC Med Imaging. 2025 Jan 17;25(1):21. doi: 10.1186/s12880-024-01533-9. BMC Med Imaging. 2025. PMID: 39825237 Free article.
40,555 results
You have reached the last available page of results. Please see the User Guide for more information.